Recent Updates
Recently added Catalysts
BBIO

NeuroVive Out-licenses Targeted LHON Therapy To BridgeBio Pharma's New Subsidiary Fortify Therapeutics

Monday, June 18, 2018 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: NeuroVive Out-licenses Targeted LHON Therapy To BridgeBio Pharma's New Subsidiary Fortify Therapeutics

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+41%
120-day peak, hindsight
Typical move
3.6%
average across 13 past catalysts
Cash runway
~30 mo
Minimal dilution risk
Lead asset
acoramidis
Phase 3 · Amyloidosis

Full Press Release Details

NeuroVive Out-licenses Targeted LHON Therapy To BridgeBio Pharma's New Subsidiary Fortify Therapeutics.
ShareAdd on Google
Tags: BBIO Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: Jun 18, 2018

Biotech snapshot

Cash runway
$720M liquidity · $24M/mo burn
~30 mo
Minimal dilution risk
Lead asset
acoramidisPhase 3
Amyloidosis →

Catalyst track record

+41%
best trade around BBIO's most recent catalyst

Peak hindsight return over a 120-day window, across 13 tracked FDA/PDUFA catalysts for BBIO.

See every catalyst's timing & PoA →